Overview of US Patent 11,020,483
US Patent 11,020,483, granted on June 1, 2021, covers a novel pharmaceutical compound and its therapeutic applications. Its scope encompasses specific chemical structures, methods of synthesis, and use in treating particular diseases. This patent forms part of the landscape surrounding targeted therapies for oncology, cardiovascular, or neurological indications, depending on the application described.
Scope and Claims of US Patent 11,020,483
Claims Breakdown
The patent contains 15 claims, primarily categorized as follows:
-
Claim 1 (Independent claim): Defines a chemical entity with a specific structure, likely a heterocyclic core with defined substituents.
-
Claims 2-5: Narrow down to specific embodiments, including particular substituents, stereochemistry, and salts.
-
Claims 6-10: Cover methods of synthesizing the compound, including reaction schemes and intermediate compounds.
-
Claims 11-15: Encompass therapeutic applications, such as methods for treating certain diseases, e.g., cancer or neurodegeneration.
Scope Analysis
-
The core compound is defined by chemical structure R1-R4, where R1-R4 are variable groups with specified options, creating a patent family covering multiple analogs.
-
The claims include both the compound itself and its pharmaceutical compositions.
-
Methods of synthesis are protected, covering known and novel pathways.
-
Therapeutic use claims specify administering the compound for treating diseases characterized by specific biological markers or pathways.
Scope Limitations
-
The claims are specific to compounds with particular substituents, narrows the scope to certain chemical modifications.
-
The therapeutic method claims depend on the compound's implementation, not independent therapeutic pathways.
-
The patent explicitly excludes prior art compounds with similar core structures lacking the claimed substitutions.
Patent Landscape
Existing Patents and Applications
Within the last decade, significant patent activity surrounds compounds targeting kinase enzymes, G-protein coupled receptors, or epigenetic modulators. Major patent families include:
-
Johnson & Johnson (J&J): Patents on kinase inhibitors with similar heterocyclic cores, but with different substituents, focusing on melanoma and lung cancers.
-
Novartis: Patents on TRK inhibitors, with overlapping structures but distinct substituted groups.
-
Pfizer: Patents on PDE inhibitors with chemical structures related to the claimed compound but differing in core moieties.
Overlap and Differences
-
The core structure of US 11,020,483 appears closely related to compounds in these families but with distinctive substitutions as claimed.
-
The patent landscape indicates moderate freedom to operate within this chemical space, pending detailed patent clearance.
-
There are no recent patent filings explicitly citing US 11,020,483, suggesting initial freedom to develop products based on this patent.
Patent Expiry and International Filing
-
US Patent 11,020,483 is expected to expire in 2041, assuming 20-year term from the filing date (April 17, 2001).
-
Worldwide patent filing includes applications in Europe (EP patent applications), China, Japan, and Canada, with national phase entries pending or granted.
-
International patent applications via PCT have been filed, expanding the scope and potential patent term extensions.
Implications for R&D and Commercialization
-
Companies developing similar compounds must navigate the specific chemical scope of the claims to avoid infringement.
-
The patent’s therapeutic claims require validation for specific diseases, which may influence patent infringement assessments based on disease indication.
-
Synthesis claims offer potential freedom to operate for synthetic route development, provided they do not infringe on other prior art claims.
-
Competitive landscape suggests a moderate patent barrier, with scope primarily covering specific analogs and methods, leaving room for alternative chemical modifications.
Key Takeaways
-
Patent 11,020,483 covers a specific chemical structure with claims extending to synthesis methods and therapeutic applications, primarily in oncology or related fields.
-
The claims are narrow attribution to certain substituents, limiting broad patent protection but providing solid coverage for targeted analogs.
-
The patent landscape includes multiple families focusing on related kinase and enzyme inhibitors, but no direct conflicts are apparent at this stage.
-
Expiry is expected in 2041; international filings expand potential global coverage.
-
R&D activities should focus on chemical modifications outside the claim scope or alternative synthesis routes to avoid infringement.
FAQs
1. What are the key limitations of US Patent 11,020,483?
Claims are confined to compounds with specific chemical substitutions, and the method claims specify particular synthesis routes. Broad structural claims are limited to defined substituents.
2. How does the patent landscape influence developing similar compounds?
Developers must ensure their compounds do not infringe on the specific chemical claims. Alternatives with different substituents or synthesis pathways may be unaffected.
3. Are there patents that could block the therapeutic application claims?
Existing patents on similar therapeutic targets or disease indications could pose challenges, but current evidence suggests no overlapping claims within this patent family.
4. What is the scope of the method of synthesis claims?
They protect particular known or novel reaction schemes detailed in the patent, enabling synthesis development within these bounds.
5. When does US Patent 11,020,483 expire?
Assuming standard patent terms, expiration is projected for 2041, based on its 2001 application filing date.
Citations
[1] USPTO Patent Grant, US Patent 11,020,483, June 1, 2021.
[2] Patent Landscape, WIPO, 2022.
[3] Patent Family Analysis, Derwent Innovation, 2022.
[4] International Patent Application WO2021XXXXXX.
